Calcified Peyronie’s Disease Frequency on Computed Tomography

Gündoğdu, elif; Emekli, Emre

doi:10.5152/tud.2022.21346

Calcified Peyronie’s Disease Frequency on Computed Tomography

Elif Gündoğdu, (Radyoloji bölümü, Eskişehir Osmangazi Üniversitesi, Tıp Fakültesi, Eskişehir, Türkiye)

Emre Emekli (Radyoloji Anabilim Dalı, Etimesgut Şehit Sait Ertürk Devlet Hastane, Ankara, Türkiye)

Turkish Journal of Urology

2 0

Yıl: 2022 Cilt: 48 Sayı: 3 Sayfa Aralığı: 196 - 200 Metin Dili: İngilizce DOI: 10.5152/tud.2022.21346 İndeks Tarihi: 13-06-2022

Calcified Peyronie’s Disease Frequency on Computed Tomography

Öz:

Objective: In computed tomography examinations performed for various reasons, calcified Peyronie’s dis- ease can be incidentally detected. In this study, we aimed to evaluate the frequency of calcified Peyronie’s disease incidentally detected in patients with abdominal computed tomography. Material and methods: The images of male patients undergoing abdominal computed tomography between January 2019 and January 2020 were retrospectively evaluated for the presence of calcified Peyronie’s dis- ease. 1968 patients remained after subtracting computed tomography scans for insufficient evaluation of the penis, evaluated for the presence of calcified Peyronie’s disease by two radiologists based on consensus. The localization, side, and the number of plaques were recorded. Results: The computed tomography examination of 1968 patients revealed calcified Peyronie’s disease in 130 (6.6%) patients. Peyronie’s disease was bilateral in 73 patients (56.1%), and unilateral in 57 (43.9%). A single plaque was observed in 44 (33.9%) patients, and multiple plaques in 86 (66.1%). The plaques were located in the middle portion of the penis in 98, proximal penis in 92, and distal penis in 31 cases. Conclusion: Calcified Peyronie’s disease is incidentally detected on computed tomography examinations at a rate not rare. Peyronie’s disease tends to be multiple, bilateral, and localized in the middle portion of the penis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359-2374. [CrossRef]
2. Ten Dam EPM, van Driel MF, de Jong IJ, Werker PMN, Bank RA. Glimpses into the molecular pathogenesis of Peyronie’s disease. Aging Male. 2020;23(5):962-970. [CrossRef]
3. Garaffa G, Trost LW, Serefoglu EC, Ralph D, Hellstrom WJ. Understanding the course of Peyronie’s disease. Int J Clin Pract. 2013;67(8):781-788. [CrossRef]
4. Gunes M, Aslan R, Eryılmaz R, Demir H, Taken K. Levels of serum trace elements in patients with Peyronie. Aging Male. 2018;17:1-4.
5. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991;146(4):1007-1009. [CrossRef]
6. Tefekli A, Kandirali E, Erol B, Tunc M, Kadioglu A. Peyronie’s disease: a silent consequence of diabetes mellitus. Asian J Androl. 2006;8(1):75-79. [CrossRef]
7. Kadioglu A, Dincer M, Salabas E, Culha MG, Akdere H, Cile- siz NC. A population-based study of Peyronie’s disease in turkey: prevalence and related comorbidities. Sex Med. 2020;8(4):679- 685. [CrossRef]
8. Habous M, Malkawi I, Han E, et al. Peyronie’s disease is common in poorly controlled diabetics but is not associated with the Meta- bolic Syndrome. Urol Ann. 2019;11(3):252-256. [CrossRef]
9. Özbir S, Değirmentepe RB, Atalay HA, et al. The role of inflam- matory parameters (neutrophil-to-lymphocyte ratio, platelet-to- lymphocyte ratio, and monocyte-to-eosinophil ratio) in patients with Peyronie’s disease. Andrology. 2020;8(2):348-352. [CrossRef]
10. De Rose AF, Mantica G, Bocca B, Szpytko A, Van der Merwe A, Terrone C. Supporting the role of penile trauma and micro-trauma in the etiology of Peyronie’s disease. Prospective observational study using the electronic microscope to examine two types of plaques. Aging Male. 2019;16:1-6.
11. Bilgutay AN, Pastuszak AW. Peyronie’s disease: a review of etiol- ogy, diagnosis, and management. Curr Sex Health Rep. 2015;7(2):117-131. [CrossRef]
12. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM, Marinko- vic JM. Risk factors for Peyronie’s disease: a case-control study. BJU Int. 2006;97(3):570-574. [CrossRef]
13. McCauley JF, Dean RC. Diagnostic utility of penile ultrasound in Peyronie’s disease. World J Urol. 2020;38(2):263-268. [CrossRef]
14. Shindel AW, Sweet G, Thieu W, Durbin-Johnson B, Rothschild J, Szabo R. Prevalence of Peyronie’s disease-like symptoms in men presenting With Dupuytren contractures. Sex Med. 2017;5(3):e135-e141. [CrossRef]
15. Rollandi GA, Tentarelli T, Vespier M. Computed tomographic findings in Peyronie’s disease. Urol Radiol. 1985;7(3):153-156. [CrossRef]
16. Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie’s disease. Urology. 2018;119:109-114. [CrossRef]
17. Parmar M, Masterson JM, Masterson TA. The role of imaging in the diagnosis and management of Peyronie’s disease. Curr Opin Urol. 2020;30(3):283-289. [CrossRef]
18. Segundo A, Glina S. Prevalence, risk factors, and erectile dysfunc- tion associated with Peyronie’s disease among men seeking uro- logical care. Sex Med. 2020;8(2):230-236. [CrossRef]
19. Shenoy-Bhangle A, Perez-Johnston R, Singh A. Penile imaging. Radiol Clin North Am. 2012;50(6):1167-1181. [CrossRef]
20. Kalokairinou K, Konstantinidis C, Domazou M, Kalogeropou- los T, Kosmidis P, Gekas A. US imaging in Peyronie’s disease. J Clin Imaging Sci. 2012;2:63. [CrossRef]
21. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19(2):213-217. [CrossRe

APA	Gündoğdu e, Emekli E (2022). Calcified Peyronie’s Disease Frequency on Computed Tomography. , 196 - 200. 10.5152/tud.2022.21346
Chicago	Gündoğdu elif,Emekli Emre Calcified Peyronie’s Disease Frequency on Computed Tomography. (2022): 196 - 200. 10.5152/tud.2022.21346
MLA	Gündoğdu elif,Emekli Emre Calcified Peyronie’s Disease Frequency on Computed Tomography. , 2022, ss.196 - 200. 10.5152/tud.2022.21346
AMA	Gündoğdu e,Emekli E Calcified Peyronie’s Disease Frequency on Computed Tomography. . 2022; 196 - 200. 10.5152/tud.2022.21346
Vancouver	Gündoğdu e,Emekli E Calcified Peyronie’s Disease Frequency on Computed Tomography. . 2022; 196 - 200. 10.5152/tud.2022.21346
IEEE	Gündoğdu e,Emekli E "Calcified Peyronie’s Disease Frequency on Computed Tomography." , ss.196 - 200, 2022. 10.5152/tud.2022.21346
ISNAD	Gündoğdu, elif - Emekli, Emre. "Calcified Peyronie’s Disease Frequency on Computed Tomography". (2022), 196-200. https://doi.org/10.5152/tud.2022.21346

APA	Gündoğdu e, Emekli E (2022). Calcified Peyronie’s Disease Frequency on Computed Tomography. Turkish Journal of Urology, 48(3), 196 - 200. 10.5152/tud.2022.21346
Chicago	Gündoğdu elif,Emekli Emre Calcified Peyronie’s Disease Frequency on Computed Tomography. Turkish Journal of Urology 48, no.3 (2022): 196 - 200. 10.5152/tud.2022.21346
MLA	Gündoğdu elif,Emekli Emre Calcified Peyronie’s Disease Frequency on Computed Tomography. Turkish Journal of Urology, vol.48, no.3, 2022, ss.196 - 200. 10.5152/tud.2022.21346
AMA	Gündoğdu e,Emekli E Calcified Peyronie’s Disease Frequency on Computed Tomography. Turkish Journal of Urology. 2022; 48(3): 196 - 200. 10.5152/tud.2022.21346
Vancouver	Gündoğdu e,Emekli E Calcified Peyronie’s Disease Frequency on Computed Tomography. Turkish Journal of Urology. 2022; 48(3): 196 - 200. 10.5152/tud.2022.21346
IEEE	Gündoğdu e,Emekli E "Calcified Peyronie’s Disease Frequency on Computed Tomography." Turkish Journal of Urology, 48, ss.196 - 200, 2022. 10.5152/tud.2022.21346
ISNAD	Gündoğdu, elif - Emekli, Emre. "Calcified Peyronie’s Disease Frequency on Computed Tomography". Turkish Journal of Urology 48/3 (2022), 196-200. https://doi.org/10.5152/tud.2022.21346